Trial Profile

A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET Kinase Inhibitor, DO-2 in Patients with Advanced or Refractory Solid Tumours

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 12 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Nov 2024 Planned End Date changed from 1 Apr 2025 to 1 Dec 2026.
07 Nov 2024 Planned primary completion date changed from 1 Oct 2024 to 1 Dec 2025.
25 Oct 2024 Results (n=10) assessing the preliminary findings from a first-in-human phase I trial of DO-2 in patients with advanced solid tumors harboring MET aberrations, aiming to determine safety and the recommended phase 2 dose (RP2D) were presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com